Skip to main content
. 2021 Oct 22;12(4):1662–1670. doi: 10.1016/j.apsb.2021.10.017

Figure 3.

Figure 3

In vivo antiviral activity of EB against ZIKV. (A) and (B) Survival percentage for four-week-old A129 male mice infected with ZIKV PRVABC59 (1.7 × 104 PFU) and treated with EB 200 mg/kg (n = 12) (A) or EB 400 mg/kg (n = 4) (B) or vehicle (n = 9) via oral gavage. (C) Survival percentage of female mice infected with ZIKV (1.7 × 105 PFU) and treated with EB 200 mg/kg (n = 15) or vehicle (n = 15). All survival curves were compared using the Log-rank test. ∗∗∗∗P < 0.0001; ∗∗P < 0.005; ∗P < 0.05.